Kinnevik AB (publ) - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.

Quarter-by-quarter ownership
Kinnevik AB (publ) ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$79,603,360
+2.4%
10,405,6680.0%100.00%0.0%
Q2 2023$77,730,340
+52.3%
10,405,668
+36.0%
100.00%
+46.0%
Q1 2023$51,045,917
-13.5%
7,653,0610.0%68.47%
+105.7%
Q4 2022$59,005,1007,653,06133.28%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
Two Sigma Ventures, LP 903,400$9,612,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders